Stock listing
NASDAQ:IRON Disc Medicine, Inc. Stock
Home listing (NASDAQ) of Disc Medicine, Inc.
Follow Disc Medicine, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IRON
$75.14 USD -2.84 (-3.6%)
Close on Nov 20, 2026
- Day range
- $74.54 – $77.01 USDNov 20, 2026
- Volume
- 561,636 sharesNov 20, 2026
- Market cap
- $3.42B USDAt the close on Nov 20, 2026 · price × 45.54M shares outstanding
- 52-week range
- $40.00 – $99.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $70.28M USDMedian day 669,013 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IRON · Home | $75.14 USD | -2.84 (-3.6%) | 561,636 | $75.20 | $77.01 | $74.54 | $77.98 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IRON · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $75.14 | -2.84 | -3.6% | $75.20 | $77.01 | $74.54 | 561,636 | |
| $77.98 | +1.41 | +1.8% | $76.52 | $79.71 | $75.25 | 947,865 | |
| $76.57 | -0.02 | 0.0% | $76.69 | $77.90 | $75.34 | 520,620 | |
| $76.59 | -3.41 | -4.3% | $80.12 | $80.37 | $76.40 | 816,009 | |
| $80.00 | -3.23 | -3.9% | $83.00 | $83.00 | $79.73 | 778,194 | |
| $83.23 | -3.85 | -4.4% | $86.16 | $87.14 | $82.66 | 761,213 | |
| $87.08 | +2.44 | +2.9% | $85.24 | $87.51 | $83.50 | 669,013 | |
| $84.64 | +3.38 | +4.2% | $80.58 | $86.26 | $80.53 | 1,925,406 | |
| $81.26 | +2.35 | +3.0% | $80.83 | $81.54 | $76.86 | 912,029 | |
| $78.91 | +0.44 | +0.6% | $78.65 | $79.52 | $77.67 | 717,525 | |
| $78.47 | -4.81 | -5.8% | $83.00 | $85.00 | $78.31 | 930,368 | |
| $83.28 | +2.12 | +2.6% | $81.50 | $83.57 | $80.78 | 1,428,044 | |
| $81.16 | +2.54 | +3.2% | $79.41 | $81.72 | $79.08 | 1,543,632 | |
| $78.62 | -2.22 | -2.7% | $80.99 | $81.39 | $78.04 | 525,360 | |
| $80.84 | -2.00 | -2.4% | $82.79 | $83.03 | $78.61 | 684,972 | |
| $82.84 | -0.36 | -0.4% | $83.51 | $85.00 | $82.22 | 686,454 | |
| $83.20 | +3.30 | +4.1% | $78.88 | $83.64 | $78.88 | 1,071,161 | |
| $79.90 | +2.24 | +2.9% | $77.23 | $80.50 | $76.50 | 1,469,720 | |
| $77.66 | +3.15 | +4.2% | $74.80 | $78.03 | $74.80 | 1,203,251 | |
| $74.51 | -0.52 | -0.7% | $74.29 | $75.56 | $74.01 | 1,963,099 | |
| $75.03 | -0.97 | -1.3% | $75.25 | $78.00 | $74.77 | 1,588,205 | |
| $76.00 | -3.48 | -4.4% | $77.80 | $81.50 | $75.89 | 4,639,550 | |
| $79.48 | +0.55 | +0.7% | $79.21 | $80.00 | $74.52 | 2,206,622 | |
| $78.93 | +22.09 | +38.9% | $72.70 | $80.22 | $69.98 | 8,493,179 | |
| $56.84 | +0.19 | +0.3% | $56.56 | $57.24 | $55.00 | 569,100 | |
| $56.65 | +0.91 | +1.6% | $56.66 | $58.09 | $55.95 | 699,800 | |
| $55.74 | -0.86 | -1.5% | $56.21 | $58.84 | $55.48 | 430,700 | |
| $56.60 | -3.88 | -6.4% | $60.16 | $60.48 | $56.47 | 599,000 | |
| $60.48 | -1.58 | -2.5% | $62.20 | $62.76 | $60.36 | 657,200 | |
| $62.06 | +1.29 | +2.1% | $60.67 | $63.50 | $60.03 | 691,100 | |
| $60.77 | -0.41 | -0.7% | $60.71 | $61.58 | $58.22 | 846,800 | |
| $61.18 | -0.47 | -0.8% | $61.20 | $62.97 | $60.02 | 562,800 | |
| $61.65 | -1.68 | -2.7% | $63.70 | $64.66 | $61.31 | 1,422,400 | |
| $63.33 | -1.18 | -1.8% | $65.13 | $65.57 | $63.01 | 456,300 | |
| $64.51 | +0.90 | +1.4% | $64.56 | $66.55 | $63.81 | 684,700 | |
| $63.61 | -1.85 | -2.8% | $65.27 | $65.94 | $63.50 | 771,800 | |
| $65.46 | -0.41 | -0.6% | $66.08 | $66.08 | $64.24 | 671,500 | |
| $65.87 | +0.95 | +1.5% | $64.93 | $66.29 | $64.05 | 784,100 | |
| $64.92 | -0.32 | -0.5% | $64.83 | $66.26 | $63.96 | 480,500 | |
| $65.24 | -1.20 | -1.8% | $66.89 | $66.89 | $64.59 | 427,200 | |
| $66.44 | +0.35 | +0.5% | $66.09 | $66.58 | $64.31 | 455,600 | |
| $66.09 | -2.39 | -3.5% | $68.54 | $68.95 | $65.31 | 541,800 | |
| $68.48 | -0.01 | 0.0% | $69.65 | $69.79 | $67.68 | 450,800 | |
| $68.49 | -1.04 | -1.5% | $69.84 | $69.84 | $67.16 | 406,500 | |
| $69.53 | +0.35 | +0.5% | $69.13 | $69.60 | $67.71 | 1,077,100 | |
| $69.18 | +0.61 | +0.9% | $69.84 | $72.07 | $68.47 | 621,200 | |
| $68.57 | +1.27 | +1.9% | $67.88 | $70.00 | $67.49 | 433,800 | |
| $67.30 | -1.62 | -2.4% | $68.86 | $69.45 | $66.72 | 603,900 | |
| $68.92 | -1.14 | -1.6% | $70.06 | $70.83 | $67.52 | 695,000 | |
| $70.06 | -4.08 | -5.5% | $74.66 | $75.00 | $69.28 | 621,000 | |
| $74.14 | -2.37 | -3.1% | $75.89 | $76.59 | $73.16 | 480,900 | |
| $76.51 | -0.33 | -0.4% | $76.55 | $77.27 | $75.24 | 719,500 | |
| $76.84 | -2.39 | -3.0% | $76.71 | $79.13 | $74.50 | 463,300 | |
| $79.23 | -0.14 | -0.2% | $78.14 | $80.01 | $78.14 | 204,800 | |
| $79.37 | -0.68 | -0.8% | $80.34 | $80.89 | $78.28 | 501,000 | |
| $80.05 | +1.38 | +1.8% | $79.44 | $81.01 | $77.68 | 522,500 | |
| $78.67 | +0.02 | 0.0% | $78.56 | $79.95 | $75.88 | 549,400 | |
| $78.65 | -1.38 | -1.7% | $79.19 | $80.53 | $77.50 | 882,000 | |
| $80.03 | -2.52 | -3.1% | $81.79 | $82.70 | $79.77 | 665,600 | |
| $82.55 | -0.12 | -0.1% | $82.25 | $83.20 | $81.10 | 324,100 | |
| $82.67 | +0.26 | +0.3% | $82.28 | $83.63 | $81.54 | 586,900 | |
| $82.41 | +1.47 | +1.8% | $81.99 | $83.59 | $81.77 | 320,944 | |
| $80.94 | +1.13 | +1.4% | $79.88 | $82.74 | $79.33 | 277,237 | |
| $79.81 | +0.97 | +1.2% | $79.50 | $80.00 | $77.99 | 370,400 | |
| $78.84 | -1.48 | -1.8% | $79.45 | $80.15 | $78.49 | 333,600 |
Splits
1 split · NASDAQ:IRON · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- NASDAQ:IRON
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Oct 19, 2026
Corporate Update (October 2026)
Corporate update · 22 slides
Latest news
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $78.47 (-5.8%) on Nov 5, 2026
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026
Closed $83.28 (+2.6%) on Nov 4, 2026
Disc Medicine to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed $78.62 (-2.7%) on Nov 2, 2026
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Oct 20, 2026
Closed $76.00 (-4.4%) on Oct 21, 2026
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
Oct 19, 2026
Closed $79.48 (+0.7%) on Oct 20, 2026
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
Oct 19, 2026
Closed $78.93 (+38.9%) on Oct 19, 2026
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
Oct 18, 2026
Closed $78.93 (+38.9%) on Oct 19, 2026
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Aug 31, 2026
Closed $78.67 (0.0%) on Sep 1, 2026
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Jul 30, 2026
Closed $79.21 (+7.5%) on Jul 30, 2026
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Jun 12, 2026
Closed $67.99 (-0.1%) on Jun 12, 2026
Disc Medicine, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 132 in all · newest Nov 5, 2026 · oldest 2021
- Decks
- 17 decks · latest Oct 19, 2026
Where Disc Medicine, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IRON · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IRON | BOATS | United States | USD |
Valuation
Price/book 5.7× against a median of 3.9×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.80B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.94
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine, Inc. · NASDAQ:IRON | US$3.42B | US$2.80B | n/a | n/a | n/a | 5.7× | n/a | 0.1× | 0.94 |
| Tango Therapeutics, Inc. · NASDAQ:TNGX | US$3.68B | US$2.74B | n/a | n/a | n/a | 3.8× | n/a | 0.0× | 1.41 |
| Xenon Pharmaceuticals Inc. · NASDAQ:XENE | US$3.64B | US$2.70B | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 0.80 |
| Relay Therapeutics, Inc. · NASDAQ:RLAY | US$3.56B | US$2.74B | n/a | 265× | n/a | 4.3× | n/a | 0.0× | 1.48 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336 | US$3.56B | US$3.42B | 7.6× | 5.1× | n/a | 2.7× | 69.9% | 0.0× | n/a |
| Enliven Therapeutics, Inc. · NASDAQ:ELVN | US$3.42B | US$2.54B | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 0.89 |
| Viridian Therapeutics, Inc. · NASDAQ:VRDN | US$3.40B | US$2.69B | n/a | 102× | n/a | 5.9× | n/a | 0.4× | 1.00 |
| Parabilis Medicines, Inc. · NASDAQ:PBLS | US$3.39B | US$2.53B | n/a | n/a | n/a | 3.4× | n/a | 0.0× | n/a |
| Caliway Biopharmaceuticals Co Ltd · TWSE:6919 | US$3.38B | US$3.27B | n/a | n/a | n/a | 12.7× | n/a | 0.0× | n/a |
| Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLX | US$3.35B | US$2.58B | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.21 |
| Iovance Biotherapeutics, Inc. · NASDAQ:IOVA | US$3.19B | US$2.86B | n/a | 7.5× | n/a | 3.9× | −58.2% | 0.1× | 1.62 |
| Median of the others | US$3.41B | US$2.72B | 7.6× | 54.9× | 3.9× | 5.8% | 0.0× | 1.21 |
Forecasts
12 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 127.69 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.11 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John Quisel | Chief Executive Officer |
| Jean Franchi | Chief Financial Officer |
| Jonathan Yu | Chief Operating Officer |
| Rahul Khara | Chief Legal Officer |
| Joseph Beaulieu | SVP, Finance |
| Melanie Chin | SVP, Clinical Development and Head of Medical Affairs |
| Sonia Razzetti | SVP, Quality |
| Srikanth Venkatraman | SVP, Head of Chemistry |
| Hua Yang | Chief Early Development Officer |
| Lisa Amaya Price | Chief Human Resources Officer |
| Pamela Stephenson | Chief Commercial Officer |
| Rahul Rajan Kaushik | Chief Technical Officer |
| Steve Caffé | Chief Regulatory Officer |
| Will Savage | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Hua Yang | Chief Early Development Officer |
| Jean Franchi | Chief Financial Officer |
| John Quisel | Chief Executive Officer |
| Jonathan Yu | Chief Operating Officer |
| Joseph Beaulieu | SVP, Finance |
| Lisa Amaya Price | Chief Human Resources Officer |
| Melanie Chin | SVP, Clinical Development and Head of Medical Affairs |
| Pamela Stephenson | Chief Commercial Officer |
| Rahul Khara | Chief Legal Officer |
| Rahul Rajan Kaushik | Chief Technical Officer |
| Sonia Razzetti | SVP, Quality |
| Srikanth Venkatraman | SVP, Head of Chemistry |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −5.8% |
| Q2 2026 | Jul 30, 2026 · Before open | +7.5% |
| Q1 2026 | May 5, 2026 · Before open | −0.1% |
| Q4 2025 | Feb 26, 2026 | −0.4% |
| Q3 2025 | Nov 6, 2025 · Before open | −1.5% |
| Q2 2025 | Aug 7, 2025 · Before open | −3.3% |
| Q1 2025 | May 7, 2025 · Before open | +2.3% |
| Q4 2024 | Mar 19, 2025 · Before open | +1.7% |
| Q3 2024 | Nov 12, 2024 · Before open | −5.0% |
| Q2 2024 | Aug 8, 2024 · Before open | +3.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +4.9% |
| Q4 2023 | Mar 21, 2024 · Before open | −7.5% |
| Q3 2023 | Nov 9, 2023 · Before open | +1.4% |
| Q2 2023 | Aug 11, 2023 · Before open | +1.7% |
| Q1 2023 | May 15, 2023 · Before open | −3.6% |
| Q4 2022 | Mar 31, 2023 · Before open | −3.9% |
| Q3 2022 | Nov 10, 2022 · Before open | +0.6% |
| Q2 2022 | Aug 11, 2022 · Before open | −4.0% |
| Q1 2022 | May 6, 2022 · Before open | −1.3% |
| Q4 2021 | Mar 10, 2022 · Before open | −3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 22 slides | Oct 19, 2026 |
| Investor Presentation (September 2026) | Investor deck | 63 slides | September 2026 |
| Investor Presentation (June 2026) | Investor deck | 41 slides | Jun 15, 2026 |
| Corporate Update (February 2026) | Corporate update | 11 slides | Feb 17, 2026 |
| J.P. Morgan 44th Annual Healthcare Conference 2026 | Conference | 31 slides | Jan 12, 2026 |
| 2025 ASH Management Call | Conference | 31 slides | Dec 8, 2025 |
| Investor Presentation (October 2025) | Investor deck | 61 slides | Oct 20, 2025 |
| 2024 ASH Management Call | Conference | 45 slides | Dec 9, 2024 |
| Corporate Update (November 2024) | Corporate update | 16 slides | Nov 4, 2024 |
| 2024 EHA Management Call | Conference | 56 slides | Jun 14, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (December 2023) | Technical | 49 slides | Dec 12, 2023 |
| ASH 2023 | Conference | 15 slides | December 2023 |
| Investor Presentation (June 2023) | Investor deck | 54 slides | Jun 9, 2023 |
| Merger or Acquisition (January 2023) | Merger or acquisition | 13 slides | Jan 23, 2023 |
| Merger or Acquisition (August 2022) | Merger or acquisition | 52 slides | Aug 10, 2022 |
| ASH 2021 (American Society of Hematology Annual Meeting) | Conference | 13 slides | Nov 8, 2021 |
| Technical Presentation | Technical | 19 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: US$450M · US$75 a share · Jefferies +6 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), LifeSci Capital, BMO Capital Markets, H.C. Wainwright & Co. Use of proceeds: Fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, pre-commercialization activities, working capital | Oct 21, 2026 |
| Public offering of common stock and pre-funded warrants Made bigger: about US$225M · US$84 a share · Jefferies +5 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), Wedbush PacGrow, H.C. Wainwright & Co. Use of proceeds: Support potential commercialization of bitopertin for EPP and XLP, fund research and clinical development, working capital and general corporate purposes | Oct 21, 2025 |
| Public offering of common stock and pre-funded warrants Made bigger: about US$225.5M · US$55 a share · Jefferies +7 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead), Cantor (co-lead), BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, H.C. Wainwright & Co. Use of proceeds: Research and clinical development of product candidates, potential commercialization of bitopertin for EPP and XLP, working capital and general corporate purposes | Jan 22, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as FS Development Corp., a blank check company (SPAC). Priced at US$10.00 a share on Aug 11, 2020.
- Price
- US$10.00 a share
- Shares offered
- 10,500,000 shares of Class A common stock
- Offering size
- US$105 million
- Underwriters' option
- Up to 1,575,000 more shares
- Listing
- FSDC on the Nasdaq Capital Market
- Underwriter
- Jefferies
- Shares delivered
- On or about Aug 14, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 2, 2020 |
| Filed publicly | Jul 24, 2020 |
| Amended once | Aug 7, 2020 |
| Shares registered with an exchange | Aug 10, 2020 |
| Declared effective by the SEC | Aug 11, 2020 |
| Final prospectus, with the price | Aug 13, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 13, 2020 |
| CERT · Exchange's certificate of listing | Aug 12, 2020 |
| EFFECT · Notice that a registration is effective | Aug 11, 2020 |
| S-1MEF · Registration of more shares for the same offering | Aug 11, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 10, 2020 |
| S-1/A · Registration statement, amended | Aug 7, 2020 |
| S-1 · Registration statement | Jul 24, 2020 |
| DRS · Draft registration statement | Jul 2, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 13, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 281.0K | 156.0K | 100.0K | 300.0K | 192.0K | 322.0K |
| Gross profit | -281.0K | -156.0K | -100.0K | -300.0K | -192.0K | -322.0K |
| Research and development | 170.6M | 96.7M | 69.3M | 33.4M | 25.2M | 28.2M |
| Selling, general and administrative | 65.4M | 33.0M | 21.9M | 14.0M | 5.76M | 5.87M |
| Operating income | -236.0M | -129.7M | -91.1M | -47.5M | -30.9M | -34.0M |
| Depreciation and amortization | 281.0K | 156.0K | 100.0K | 89.0K | 32.0K | 322.0K |
| EBITDA | -235.7M | -129.6M | -91.0M | -47.4M | -30.9M | -33.7M |
| Interest expense | 3.61M | 572.0K | 0 | 737.0K | 2.16M | 6.83M |
| Income before tax | -211.8M | -109.0M | -76.3M | -46.8M | -36.0M | -40.8M |
| Income tax | 361.0K | 355.0K | 99.0K | 0 | 5.04M | 6.83M |
| Net income | -212.2M | -109.4M | -76.4M | -46.8M | -36.0M | -40.8M |
| Earnings per share, basic | -6.01 | -3.96 | -3.42 | -45.05 | -40.95 | -2.70 |
| Earnings per share, diluted | -6.01 | -3.96 | -3.42 | -45.05 | -40.95 | -2.70 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 91.1M | 192.4M | 360.4M | 194.6M | 88.0M | 4.50M |
| Short-term investments | 700.0M | 297.4M | 0 | |||
| Current assets | 803.9M | 493.6M | 365.7M | 198.5M | 90.5M | 5.07M |
| Property, plant and equipment | 1.16M | 751.0K | 170.0K | 168.0K | 106.0K | 294.0K |
| Total assets | 806.9M | 496.8M | 368.0M | 200.2M | 92.4M | 8.32M |
| Accounts payable | 9.02M | 7.95M | 12.6M | 16.2M | 2.56M | 2.38M |
| Current liabilities | 36.6M | 23.3M | 21.4M | 22.6M | 13.4M | 24.9M |
| Long-term debt | 29.2M | 28.3M | 404.0K | 4.95M | ||
| Total debt | 29.2M | 28.3M | 0 | 1.33M | 7.06M | 14.0M |
| Total liabilities | 67.1M | 53.2M | 22.9M | 23.6M | 14.8M | 30.2M |
| Shareholders' equity | 739.8M | 443.6M | 345.1M | 176.6M | -64.2M | -28.8M |
| Shares outstanding | 37.9M | 29.9M | 24.4M | 17.4M | 909.4K | 15.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -180.4M | -93.9M | -73.5M | -42.3M | -27.5M | -32.7M |
| Capital spending | -933.0K | -505.0K | -89.0K | -151.0K | -68.0K | -22.0K |
| Free cash flow | -181.3M | -94.4M | -73.6M | -42.4M | -27.6M | -32.7M |
| Cash from investing | -394.3M | -292.3M | -89.0K | -151.0K | -68.0K | -22.0K |
| Cash from financing | 473.4M | 218.3M | 239.4M | 149.0M | 89.9M | 34.2M |
| Change in cash | -101.3M | -167.9M | 165.8M | 106.6M | 62.3M | 1.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 22, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 21, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Oct 19, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Oct 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 19, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 27, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 8-K · Current report | Feb 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 17, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 22, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 22, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 21, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Oct 20, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 20, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 15, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Aug 5, 2025 | Other filings | SEC |
This page holds 200 of 780 filings. Open Filings
Cap table
Built by 6ix from Disc Medicine, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 45,540,842
- Fully diluted
- 45,540,842
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 45,540,842 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 45,540,842 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jean George Other companies: Cyteir Therapeutics Inc (Director · Jun 17, 2021 – Feb 14, 2024 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); Calithera Biosciences, Inc. (Director · Oct 1, 2014 – Jun 11, 2021 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Jan 22, 2020 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 28, 2013 · Past); Zeltiq Aesthetics Inc (Director · Oct 18, 2011 – Jul 22, 2015 · Past) | Director · Feb 5, 2021 – Feb 5, 2021 · Past |
| Jason Rhodes Other companies: Dyne Therapeutics, Inc. (Chairman · Since at least Sep 16, 2020); Generation Bio Co (Director · Since at least Jun 11, 2020); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2022 · Past); Epizyme Inc (President, CFO and Treasurer · May 30, 2013 – Sep 22, 2014 · Past) | Director · Feb 5, 2021 – Oct 4, 2021 · Past |
| Brian Piekos Other companies: KalVista Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Sep 9, 2024); Elicio Therapeutics, Inc. (Chief Financial Officer · Jun 1, 2023 – Feb 1, 2024 · Past); AMAG Pharmaceuticals Inc (Chief Financial Officer · Jun 9, 2020 – Nov 16, 2020 · Past) | CFO · Feb 12, 2021 – May 31, 2022 · Past |
| Jean Franchi Other companies: Biodesix, Inc. (Director · Since at least Oct 27, 2020); Replimune Group, Inc. (Chief Financial Officer · Dec 9, 2019 – May 16, 2023 · Past); Merrimack Pharmaceuticals Inc (Chief Financial Officer · Feb 15, 2018 – Dec 11, 2018 · Past) | Chief Financial Officer · Since at least Feb 7, 2024 |
| Nadim Ahmed Other companies: Cullinan Therapeutics, Inc. (President and Chief Executive Officer · Since at least Oct 18, 2021); Bristol-Myers Squibb Company (EVP and President, Hematology · Nov 20, 2019 – Dec 31, 2020 · Past); Celgene Corporation (PRES., GLOBAL HEM. AND ONC. · Jun 13, 2018 – Nov 20, 2019 · Past) | Director · Since at least Jul 14, 2025 |
| Donald William Nicholson Other companies: Generation Bio Co (Director · Since at least Jan 11, 2021); Kymera Therapeutics, Inc. (Director · Jun 16, 2021 – Jun 15, 2022 · Past) | Director · Since at least Dec 29, 2022 |
| Georges Gemayel Other companies: Supernus Pharmaceuticals, Inc. (INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Feb 21, 2020); Momenta Pharmaceuticals Inc (Director · Jun 19, 2019 – Oct 1, 2020 · Past) | Director · Since at least Apr 29, 2021 |
| Gregg Beloff Other companies: Pandion Therapeutics Inc (See Remarks · Jul 16, 2020 – Apr 1, 2021 · Past); Synlogic Inc (See Remarks · Oct 21, 2019 – Dec 6, 2021 · Past) | Chief Financial Officer · Feb 5, 2021 – Feb 5, 2021 · Past |
| John Quisel Other companies: Gossamer Bio, Inc. (Director · Since at least Nov 28, 2023); Acceleron Pharma Inc (EVP, Chief Business Officer · Sep 18, 2013 – Jan 2, 2020 · Past) | Chief Executive Officer · Since at least Dec 29, 2022 |
| Kevin Bitterman Other companies: Akero Therapeutics Inc (Director · Jun 19, 2019 – Jun 1, 2021 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past) | Director · Since at least Dec 29, 2022 |
All 33 people
| Person | Seat |
|---|---|
| Mona Ashiya Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Sierra Oncology Inc (Director · Jun 8, 2021 – Jul 1, 2022 · Past) | Director · Since at least Dec 29, 2022 |
| Pamela Stephenson Other companies: Zynerba Pharmaceuticals Inc (Director · Jun 14, 2022 – Oct 10, 2023 · Past); Albireo Pharma Inc (Chief Commercial Officer · Apr 22, 2022 – Mar 2, 2023 · Past) | Chief Commercial Officer · Since at least Feb 26, 2024 |
| William Richard White Other companies: Akero Therapeutics Inc (Chief Financial Officer · Since at least Jun 10, 2025); Ventyx Biosciences Inc (Director · Since at least Jun 5, 2025) | Director · Since at least Jun 11, 2025 |
| Daniel Dubin Other companies: Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past) | Director · Aug 11, 2020 – Aug 11, 2020 · Past |
| Dennis D Ryan Other companies: Pardes Biosciences Inc (Chief Financial Officer · Feb 16, 2021 – Feb 16, 2021 · Past) | Chief Financial Officer · Aug 11, 2020 – Aug 11, 2020 · Past |
| Joseph Beaulieu Other companies: Epizyme Inc (See Remarks · Aug 9, 2022 – Aug 12, 2022 · Past) | SVP, Finance · Since at least Nov 5, 2026 |
| Samuel B Barone Other companies: Adverum Biotechnologies Inc (SVP, Clinical Development · Jul 30, 2014 – Feb 9, 2017 · Past) | Chief Medical Officer · Apr 12, 2021 – Apr 12, 2021 · Past |
| Brian Richard MacDonald | Chief Innovation Officer · Dec 29, 2022 – Jun 28, 2023 · Past |
| Hua Yang | Chief Early Development Officer · Since at least Nov 5, 2026 |
| Jason Patrick Meyenburg | Chief Executive Officer, Director · Feb 5, 2021 – Jan 3, 2022 · Past |
| Jonathan Yu | Chief Operating Officer · Since at least Dec 29, 2022 |
| Lisa Amaya Price | Chief Human Resources Officer · Since at least Jan 12, 2026 |
| Marc Uknis | Chief Medical Officer · Feb 5, 2021 – Feb 5, 2021 · Past |
| Mark Chin | Director · Since at least Jun 11, 2025 |
| Melanie Chin | SVP, Clinical Development and Head of Medical Affairs · Since at least May 14, 2025 |
| Precillia Redmond | Chief People Officer · Feb 5, 2021 – Feb 23, 2021 · Past |
| Rahul Khara | Chief Legal Officer · Since at least Dec 29, 2022 |
| Rahul Rajan Kaushik | Chief Technical Officer · Since at least Nov 12, 2024 |
| Sonia Razzetti | SVP, Quality · Since at least Nov 5, 2026 |
| Srikanth Venkatraman | SVP, Head of Chemistry · Since at least Nov 5, 2026 |
| Steve Caffé | Chief Regulatory Officer · Since at least Nov 12, 2024 |
| William Jacob Savage | Chief Medical Officer · Since at least Dec 29, 2022 |
| Will Savage | Chief Medical Officer · Since at least Apr 15, 2026 |
Log in to ask 6ix AI your own questions about Disc Medicine, Inc.